New Systems Will Improve the Treatment Process Workflow, Enabling Clinicians to Treat More Patients Every Day
SUNNYVALE, California, March 28, 2018 /PRNewswire/ -- Personalized, precise, radiation treatments will soon be available to more cancer patients in India. Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with the Apollo Hospitals Group in Chennai and New Delhi, India, for the acquisition of two Radixact® Systems, radiation therapy devices that have been proven to deliver highly accurate treatments for a broad range of tumors anywhere in the body. The installation of these systems, one replacing a conventional linear accelerator and the other in a new vault, will expand access to state-of-the-art cancer treatment technology for the people of India. The orders were entered into backlog during Accuray Incorporated's Q3 fiscal quarter, which ends March 31, 2018.
Apollo Hospitals was established in 1983 and has since emerged as Asia's foremost integrated healthcare services provider. This patient-centric organization's mission is to bring the highest standards of healthcare to every patient.
Dr. Prathap C. Reddy, Chairman, Apollo Hospitals Group said, "Cancer care requires passionate commitment, cutting edge expertise along with unswerving dedication to keep raising the bar and at Apollo we have embraced this ethos, as our singular goal is to make cancer conquerable!"
Dr. Reddy added, "For over twenty–five years, Apollo Cancer Centres have been serving patients from over 140 countries. Our fine teams of Oncologists persevere relentlessly to offer patients the global best in cancer care and a contemporary product such as the Radixact System will help our patients by minimizing the impact on their quality of life."
Radixact System Benefits
The platform features a more powerful linear accelerator than prior generations, as well as integrated 3D CTrue™ imaging and helical treatment delivery, which enable physicians to deliver very accurate, individualized dose distributions that precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients
Daily 3D image guidance, which facilitates proper patient positioning and dose targeting even when anatomical changes occur, helps ensure treatment accuracy is achieved. Clinicians are able to easily see the patient anatomy every day as part of the streamlined delivery workflow, so that they know exactly where the tumor is on that particular day
The treatments are both highly efficient and effective, expanding the reach of radiation therapy and enabling previously untreatable cases to be treated with ease – and with a seamless process
Adaptive therapy, using PreciseART™ Adaptive Radiation Therapy software, is highly automated and efficient, enabling the clinical team to routinely incorporate adjustments to the treatment planning and delivery process based on changes in tumor size, shape and location — as well as subtle changes in the location of organs and other healthy tissue
"We are honored to be partnering with Apollo Hospitals to improve the lives of people with cancer. Our employees are focused on a common goal – to put patients first by providing them with the best possible care," said Lionel Hadjadjeba, M.D., Senior Vice President, and Chief Commercial Officer at Accuray. "The Radixact® System can be used to treat virtually any tumor type including breast, head and neck, lung and prostate cancers, during every stage of the treatment journey, from primary cases, to recurrent and metastatic diseases. This gives the Apollo Hospitals clinical team tremendous flexibility and enables them to tailor treatments to the specific needs of each patient."
About Apollo Hospitals Group Apollo Hospitals was established in 1983 by Dr. Prathap C. Reddy. It was India's first corporate hospital, and is acclaimed for pioneering the private healthcare revolution in the country. Since then, Apollo has risen to a position of leadership and has emerged as Asia's foremost integrated healthcare services provider. It has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics.
In a rare honour, the Government of India issued a commemorative stamp in recognition of Apollo's widespread contributions, the first for a healthcare organization. Dr. Prathap C. Reddy, Founder Chairman of the Apollo Hospitals Group has been conferred with the prestigious Padma Vibhushan, India's second highest civilian award. For more information, please visit www.apollohospitals.com or follow us on Facebook, Twitter, Blog, YouTube, LinkedIn, SlideShare and Instagram
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and Accuray's ability to continue to penetrate the global radiation therapy market. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, the company's ability to develop new products or enhance existing products to meet customers' needs, the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2017, the company's quarterly report on Form 10-Q, filed with the SEC on February 5, 2018 and as updated periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.